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receiving ESPs was calculated by chemotherapy cycle, Hb level
during each cycle, and year. RESULTS: A total of 13,069 cancer
patients were studied. Median age was 61 years, 60% were
female, 38% had ECOG PS 0–2, and 30% had metastases.
Forty-four percent had solid malignant tumors of which breast,
lung and colorectal cancer were most common. Lymphoma was
the most common hematologic cancer. The percentages of
patients receiving ESPs during the initial cycle of the ﬁrst planned
chemotherapy regimen were 46.1%, 48.9%, and 48.2% at Hb
°Ü 10 g/dL; 44.5%, 52.7%, and 51.4% at Hb level of >10 to
<11 g/dL, in years 2004, 2005, and the ﬁrst 10 months of 2006
respectively. Across all years, the proportion of patients receiv-
ing ESPs at Hb < 11 g/dL was 49.1%. Few patients (2.6–4.1%)
with Hb °Y´ 12 g/dL received ESPs. CONCLUSION: ESP use
changed little over time. The overall proportion was under 50%
in patients with Hb < 11 g/dL, the guideline-recommended range
for ESP initiation. Further research is needed to understand the
reasons for apparent under-utilization of ESPs in community
oncology practices.
CANCER—Methods & Concepts
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OBJECTIVES: Establishment of a common unit for measuring
health can be helpful for health policy decision. The objective of
this study is to develop a common method and health unit for
comparative assessment for health outcome. METHODS: By
adjusting survival function with the mean of quality of life at
every time point ti and then summing up throughout lifetime, we
come up with a quality-adjusted life expectancy (QALE), which
has a common unit of quality-adjusted life year (QALY). QALE
= ∫ E(qol(ti/Xi))S(ti/Xi)dt where E(qol(ti/Xi)) is the expected
value of quality of life function at time ti and S(ti/Xi) is the sur-
vival function at time ti. Our approach is empirically imple-
mented on estimating potential impacts of following health
issues: the enforcement of helmet law in Taipei city and the con-
tamination of underground water by chlorinated hydrocarbons
from an electronics factory. RESULTS: The results showed that
there would be 1300 cases with head injury annually prevented
in Taipei city, which amounted to 6240 QALY saved. A case of
hepatocellular carcinoma was estimated to lose 19.5 QALY.
While the estimated likelihood from pollution of vinyl chloride,
trichloroethylene, and tetrachloroethylene in the ground water
were 8.4 × 10(−6), 1.4 × 10(−4), and 1.9 × 10(−4) based on
cancer slopes. Assuming that the population at risk in the
exposed community were about 1000 people, then the estimated
potential health impact would be a loss of 2, 32, and 44 QALM
(quality-adjusted life month), accordingly. We further extend the
method to psychometry and a unit of score-time and conduct
outcome evaluation for the effect of bone marrow transplanta-
tion after chemotherapy for acute myelogenous leukemia. CON-
CLUSION: We conclude that the method is feasible for
comparative health risk/outcome assessment for public health
and clinical policy decisions.
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OBJECTIVES: To estimate the cost-utility of two major strate-
gies for treating ALL in childhood, for informing decisions in 
the publicly-funded health care system of Ontario Canada.
METHODS: Most children diagnosed in Ontario with ALL are
treated according to Berlin-Frankfurt-Munster (BFM) or Dana-
Farber Cancer Institute (DFCI) protocols. The total cost of
health care resource utilization from diagnosis through end of
treatment will be based on mean total RIWs per patient treated
at two tertiary care centers in Ontario: one using BFM and the
other using DFCI. RIW data will be obtained from existing
administrative datasets. Cost per RIW will be standardized
across centers. Quality-adjusted life years (QALYs) will be based
on HUI health status surveys of patients, during (n > 300) 4 or
5 therapy phases (n > 316) and after therapy (n > 468).
RESULTS: This is the ﬁrst cost-utility study combining costs
based on RIWs, and QALYs from HUI measurements. RIWs
were developed, and are routinely used, for the funding and
administration of hospitals in Ontario. The HUI is a practical
tool for measuring the utility of overall health status, and has
been validated in many ALL studies. HUI surveys of numerous
patients will provide precise estimates of mean utility for QALYs.
No other study has surveyed these types of patients across treat-
ment phases. CONCLUSION: This is a useful approach that
bases costs and QALYs on valid, prospective measurements.
Validity of the RIW costing measurement system is well recog-
nized by administrators and health care policy analysts. Major
institutions, including Statistics Canada that has included the
HUI in every major population health survey since 1990, have
recognized the validity of HUI. The recognized validity of RIW
and HUI measures is expected to make the results appealing to
decision-makers.
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OBJECTIVES: Although the number needed to treat to prevent
a case of disease is a commonly used metric, the number needed
to vaccinate (NNV) is relatively new. We determined how adding
a quadrivalent human papillomavirus (6/11/16/18) vaccine to
screening in the U.S. would reduce the burden of HPV related-
disease using the NNV. METHODS: A Markov model of the
natural history of HPV infection incorporating screening and
vaccination was developed. A vaccine that prevents 100% of
HPV 6, 11, 16 and 18-associated disease, with a lifetime dura-
tion and 70% coverage, in conjunction with current screening
was compared to screening only. The NNV was calculated based
on the difference in the risk of genital warts, cervical pre-cancer
(deﬁned as cervical intraepithelial neoplasia 1, 2, or 3) or cancer
achieved with vaccination and screening compared to screening
only for a cohort of girls aged 12 years. We also estimated the
NNV for cohorts aged 13 to 26 years to account for recent
Centers for Disease Control Advisory Committee on Immuniza-
tion Practices (ACIP) recommendations. RESULTS: The NNV
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varied from 19 for warts, to 27 for CIN 3 and approximately
450 for cancer and was similar for the differently aged cohorts.
Results were sensitive to the duration of vaccine efﬁcacy and cov-
erage. If vaccine coverage was as low as 30%, the NNV for
warts, CIN 3 and cancer would increase to 50, 57 and 1115
respectively. If the duration of efﬁcacy was only 10 years instead
of a lifetime, the NNV would increase to 62 for warts, 67 for
CIN 3 and over 1100 for cancer. CONCLUSION: These analy-
ses suggest that the NNV for warts and cervical pre-cancer using
a quadrivalent HPV vaccine is low, but will depend on the dura-
tion of vaccine efﬁcacy as well as coverage.
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OBJECTIVES: The Functional Assessment of Cancer Therapy—
Kidney Symptom Index (FKSI) is a 15-item scale that was devel-
oped and validated to assess symptoms and concerns of
advanced kidney cancer patients. The aim of this study was to
evaluate the factor structure of FKSI for possibly useful sub-
scales and assess the reliability of the sub-scales. METHODS:
Data for this study were obtained from a phase III clinical trial
of 903 advanced renal cancer patients. Patients were adminis-
tered FKSI questionnaire at baseline. Baseline data were analyzed
using exploratory factor analysis with oblique rotation (promax)
to evaluate the dimensional structure of FKSI. The internal con-
sistency of the subscales and overall scale was assessed using
Cronbach’s alpha. RESULTS: Four factors were identiﬁed con-
sisting of 13 of the 15 items of FKSI. The ﬁrst factor had two
items related to pain symptoms; the second factor had two items
related to respiratory symptoms; the third factor had ﬁve items
related to general symptoms of the disease and; the fourth factor
had four items related to quality of life. All four factors had good
reliability (alphas > 0.70). The internal consistency of the overall
13-item scale was excellent (alpha = 0.83). CONCLUSION: A
four-factor solution consisting of 13 items could easily be labeled
with clinically-meaningful concepts, indicating the possibility of
four underlying dimensions of kidney cancer symptomatology:
pain, respiratory, general symptoms and quality of life. Findings
supported the internal consistency of four sub-scales and overall
13-item scale. Sub-scale scores and the total index are reliable
and valid measure that can be used to determine the effect of
drug therapies on speciﬁc symptoms and concerns of advanced
kidney cancer.
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OBJECTIVES: To assess Australian men’s preferences for health
states (HS) speciﬁc to advanced stage prostate cancer (APC)
including baseline diagnoses of APC, response, no response,
disease progression and especially treatment-related toxicities by
severity apart from other components of the HS which is
methodologically different. METHODS: FACT-P QOL data
from patients with APC were used to compose HS narratives
consisting of physical, social, emotional, functional well-being,
additional concerns domains. Treatment-related mild, moderate,
severe and life-threatening toxicities were described separately.
100 Australian men were recruited and interviewed using stan-
dard gamble techniques (SG). Baseline diagnoses of APC,
response, no response and disease progression using SG as usual
with oscillating risks of perfect health (1) and immediate death
(0) as anchors OR the HS narrative with 100% certainty. For
toxicities, however, the true trade-off is treatment response with
an associated risk of toxicity OR no treatment and remain with
100% certainty at baseline APC. This obtains how much chance
of response a man needs to be indifferent to the corresponding
chance of toxicity by severity. RESULTS: SG regression results
were 0.506 (p < 0.01) for baseline APC, 0.602 (p < 0.01) for
response, 0.502 (p < 0.01) for no response, and 0.318 (p < 0.01)
for disease progression. The trade-off between a chance of treat-
ment response with a corresponding chance of mild, moderate,
severe, or life-threatening toxicity yielded utility scores of 0.794
(p < 0.01), 0.715 (p < 0.01), 0.466 (p < 0.01), and 0.257 (p <
0.01), respectively. CONCLUSION: Men need at least a 21%,
28%, 55% or 74% chance of treatment response to be indiffer-
ent to treatment related toxicity depending on severity. These
measured values are more appropriate for Quality-adjusted Time
Without Symptoms of disease and Toxicity (Q-TWiST) analysis
where time without disease progression is rewarded while disease
progression with toxicities is penalized by applying a utility
weights for disease progression and time with toxicity than the
usual arbitrary ones.
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OBJECTIVES: The purpose of this study was to translate and
linguistically validate the Functional Assessment of Cancer
Therapy—Head and Neck V. 4 (FACT-H&N) for Gujarati,
Hindi, Kannada, Malayalam, Marathi, Tamil, Telugu and Urdu
translations. METHODS: The FACT-H&N was originally devel-
oped through patient and expert interviews, and validation
studies. The FACT-H&N was translated according to the stan-
dard FACIT methodology: 2 forward translations, a reconciled
version of the 2 forwards, back-translation to English, 3 inde-
pendent reviews by bilingual experts, and harmonization across
all languages. The study sample included 120 patients from 8
regions of India. Patients diagnosed with any type of head and
neck cancer completed the translated FACT-H&N and then par-
ticipated in cognitive debrieﬁng interviews. Statistical analyses
(descriptive statistics and reliability analyses) were performed on
the quantitative data, and the participant comments were ana-
lyzed qualitatively. RESULTS: Most of the languages showed
acceptable reliability ranging from 0.69 to 0.87 for the H&N
subscale despite the small sample size with the exception of
Kannada (0.13) and Tamil (0.56). There were no negative patient
comments related to the H&N speciﬁc items. However, when
item-total correlations were examined, it was found that some
items performed poorly across some languages. They included
mouth dryness, trouble breathing, and communication with
others. Of these, only the item about communication seemed to
indicate a cultural issue affecting the item’s relevance. Small
changes were made to the Telugu translation but not to the other
languages. CONCLUSION: The FACT-H&N has shown good
reliability and linguistic validity with 8 language versions. We
consider these translations to be acceptable for use in interna-
